SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned The Chemical Drug Name 'Sumifilam' By USAN

AUSTIN, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that its lead drug candidate PTI-125 has

Benzinga · 08/24/2020 12:19

AUSTIN, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that its lead drug candidate PTI-125 has been assigned the chemical drug name sumifilam by the United States Adopted Names (USAN) Council. Future references to PTI-125 will be sumifilam. A commercial brand name for sumifilam is expected to be announced at a future date. Sumifilam is an investigational new drug and has not been approved for any indication.

Sumifilam is the first of a new class of drugs that bind filamin proteins. For this reason, USAN is expected to grant this class of drugs its own name stem, i.e., -filam. Any future drug by any company that targets filamin protein is expected to incorporate the -filam name stem as part of its drug name.

"A very famous author once asked, what's in a name?" said Remi Barbier, President & CEO. "With apologies to that author, that which we call sumifilam by any other name would still elicit palpable excitement for an absolutely new type of drug therapy for Alzheimer's disease."